Begin main content

New at CADTH - November 2019

November 7, 2019
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.

Drug Reimbursement Recommendation - Idhifa and Vitrakvi

October 31, 2019
Today, CADTH has issued final recommendations for: Enasidenib (Idhifa) for Acute Myeloid Leukemia Funding Request: For the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation Recommendation: Do not reimburse Notification to implement target date: November...

Drug Reimbursement Recommendation - Xultophy

October 28, 2019
Today, CADTH has issued final recommendations for: insulin degludec + liraglutide (Xultophy) Indications: Diabetes mellitus, Type 2 Recommendation: Reimburse with clinical criteria and/or conditions For more information

Call for Patient Input and Clinical Experts: semaglutide

October 24, 2019
CADTH has received the following notice(s) of pending drug submission(s). Brand name TBC Generic name semaglutide Manufacturer Novo Nordisk Canada Inc. Indication(s) diabetes mellitus, type 2 Project Number SR0637-000 Call for patient input 2019-10-24 Patient input...

Drug Reimbursement Recommendation - Botox

October 22, 2019
Today, CADTH has issued final recommendations for: onabotulinumtoxinA (Botox) Indications: Migraine, chronic Recommendation: Reimburse with clinical criteria and/or conditions For more information